O
Oriva Therapeutics
Oriva Therapeutics is a clinical-stage women's health biotechnology company based in Barcelona, developing first-in-class and best-in-class therapies for chronic, prevalent gynaecological diseases with high unmet need, with two advanced programmes in endometriosis and uterine fibroids. It launched in 2026 with an undisclosed pre-seed round from Asabys Partners' Sabadell Asabys II fund, built by spinning out two clinical-stage assets from Galician biotechs Oncostellae and Medibiofarma, and appointed Dr Agnès Arbat (ex-Oxolife co-founder/CEO, ex-Bayer, ex-Organon) as CEO and CMO in June 2026. The entity was created by Asabys around Julio Castro-Palomino's chemistry assets.
SectorsBiotech, Women's Health, Pharmaceuticals, Healthtech & Bio
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
A
Agnès Arbat
Chief Executive Officer & Chief Medical Officer
J
Julio Castro-Palomino
Co-founder (originator of Oriva's assets; founder of Oncostellae and Medibiofarma)
Also at Palobiofarma
+3
Global models 5
OObsEva
Switzerland · www.obseva.com ↗
Women's health biotech built on in-licensed clinical-stage assets for endometriosis and uterine fibroids (linzagolix), exactly Oriva's therapeutic focus and asset-sourcing model.
$240MComparable
HHope Medicine
China · www.hopemedicine.com ↗
Clinical-stage biotech developing first-in-class biologics for endometriosis and other gynaecological diseases, funded by venture capital to take them through the clinic.
$100MComparable
F
Forendo Pharma
Finland · www.forendo.com ↗
VC-backed biotech developing a first-in-class HSD17B1 inhibitor for endometriosis through clinical trials, then exiting through a sale to Organon, the asset-to-pharma path Oriva is set up for.
$60MComparable
GGesynta Pharma
Sweden · www.gesynta.se ↗
Clinical-stage company developing a first-in-class non-hormonal drug (vipoglanstat) for endometriosis, a chronic, common gynaecological disease with high unmet need.
$60MComparable
K
KaNDy Therapeutics
United Kingdom
Single-asset women's health biotech that in-licensed a clinical compound for menopause symptoms, took it through Phase 2 on VC money and sold it to Bayer, the same lean asset-centric model as Oriva.
$40MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 1
Open as list →
Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-08 | Pre-seed | — | Asabys Partners |
News 2
Open as list →| Published | Article |
|---|---|
| 2026-06-11 |
Oriva appoints Agnès Arbat as CEO as endometriosis drug enters clinic ↗
The Pharma Letter
2026-06-11 |
| 2026-01-22 |
Asabys-backed Oriva Therapeutics launches to advance novel treatments for women's health ↗
Biotech Spain
2026-01-22 |